HEMLIBRA: payments to doctors
Payments that named HEMLIBRA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.4M
- Providers
- 959
- Transactions
- 4,858
- Average per transaction
- $1,526
The per-transaction average — $1,526 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 959 providers the average total is $7,732, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $4,145,248 | 55.9% |
| Genentech USA, Inc. | $2,832,988 | 38.2% |
| F. Hoffmann-la Roche AG | $364,615 | 4.9% |
| Roche Products Limited | $44,996 | 0.6% |
| Hoffmann-la Roche Limited | $27,457 | 0.4% |